Core Viewpoint - Qingdao Baiyang Pharmaceutical Co., Ltd. has signed a strategic cooperation agreement with Peking University International Hospital to establish a precision radiotherapy center, focusing on innovative treatment solutions for brain tumor patients [1][2]. Group 1: Strategic Cooperation - The cooperation aims to build a high-level radiotherapy platform centered on specialized treatment for brain tumors, utilizing the ZAP-X radiotherapy robot [1][2]. - The partnership is seen as a new starting point for both parties, with aspirations to enhance diagnostic and treatment capabilities in the field of oncology, particularly for brain tumors [2]. Group 2: Technology and Innovation - The ZAP-X technology is described as revolutionary in the field of cranial radiotherapy, significantly improving the precision and safety of brain tumor treatments [2]. - ZAP-X employs a unique dual-rotating spherical structure, allowing X-rays to target tumors from thousands of non-coplanar angles, effectively destroying tumors while protecting surrounding healthy brain tissue [2]. - The device has achieved approvals in 24 countries and regions globally, with over 5,000 clinical treatments completed [2]. Group 3: Company Development - Baiyang Pharmaceutical is advancing its transformation into a technology-driven enterprise, focusing on optimizing medical scenarios through technological innovation [3]. - The company has established a comprehensive industrial chain in the radiotherapy field, covering research and development, production, and operation [3]. - Baiyang aims to continue building precision radiotherapy centers and applying advanced radiotherapy equipment in clinical settings to benefit more patients in China [3].
百洋医药脑肿瘤精准放疗中心签约落地 放疗商业化进程提速